JP5146643B2 - Orally administered adsorbent with excellent adsorption characteristics of nitrogen-containing compounds and method for producing the same - Google Patents
Orally administered adsorbent with excellent adsorption characteristics of nitrogen-containing compounds and method for producing the same Download PDFInfo
- Publication number
- JP5146643B2 JP5146643B2 JP2007153182A JP2007153182A JP5146643B2 JP 5146643 B2 JP5146643 B2 JP 5146643B2 JP 2007153182 A JP2007153182 A JP 2007153182A JP 2007153182 A JP2007153182 A JP 2007153182A JP 5146643 B2 JP5146643 B2 JP 5146643B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- clay
- acid treatment
- particle size
- orally administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003463 adsorbent Substances 0.000 title claims description 34
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title description 17
- 238000001179 sorption measurement Methods 0.000 title description 8
- 239000004927 clay Substances 0.000 claims description 68
- 239000002245 particle Substances 0.000 claims description 57
- 238000010306 acid treatment Methods 0.000 claims description 43
- 229910021647 smectite Inorganic materials 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 24
- 238000005469 granulation Methods 0.000 claims description 14
- 230000003179 granulation Effects 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 12
- 238000005096 rolling process Methods 0.000 claims description 9
- 230000001066 destructive effect Effects 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 238000000790 scattering method Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 30
- 229910052782 aluminium Inorganic materials 0.000 description 29
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 29
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 15
- 229940109239 creatinine Drugs 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- -1 hydrogen ions Chemical class 0.000 description 11
- 230000000704 physical effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002002 slurry Substances 0.000 description 10
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 229940116269 uric acid Drugs 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- 229910004298 SiO 2 Inorganic materials 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000440 bentonite Substances 0.000 description 5
- 229910000278 bentonite Inorganic materials 0.000 description 5
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011362 coarse particle Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910004283 SiO 4 Inorganic materials 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical group 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N methylguanidine Chemical compound CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000004438 BET method Methods 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000669 biting effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Description
本発明は、含窒素化合物の吸着特性に優れた経口投与吸着剤に関するものであり、より詳細には、ヒト、家畜などの腎機能が低下したときに生体内に蓄積される含窒素化合物を経口投与により有効に吸着除去できる経口投与吸着剤に関する。 The present invention relates to an orally administered adsorbent having excellent adsorption characteristics of nitrogen-containing compounds. More specifically, the present invention relates to oral administration of nitrogen-containing compounds accumulated in a living body when kidney function is reduced in humans, livestock, etc. The present invention relates to an orally administered adsorbent that can be effectively adsorbed and removed by administration.
豚、鶏、牛、羊などの家畜や犬、猫などのペット(以下、家畜類と呼ぶ)やヒトの排泄物中には、タンパク質代謝の産物として、尿素、クレアチニン、尿酸などの含窒素化合物が排泄物中に含まれている。このような含窒素化合物を、腎臓のろ過分離機能によって生成排泄することにより、有毒物や不要物質の生体内への蓄積を回避し、また体液浸透圧の調節、酸−塩基平衡の調節が行われている。従って、腎機能が低下すると、生体内に上記のような含窒素化合物が蓄積し、尿毒症や意識障害など、生体に障害を生じるようになってしまう。 Nitrogen-containing compounds such as urea, creatinine, and uric acid are found as products of protein metabolism in domestic animals such as pigs, chickens, cows, and sheep, pets such as dogs and cats (hereinafter referred to as domestic animals), and human excreta. Is contained in the excreta. Such nitrogen-containing compounds are produced and excreted by the filtration and separation function of the kidney, thereby avoiding the accumulation of toxic substances and unnecessary substances in the living body, and adjusting body fluid osmotic pressure and acid-base equilibrium. It has been broken. Accordingly, when the renal function is lowered, the nitrogen-containing compounds as described above accumulate in the living body, which causes damage to the living body such as uremia and impaired consciousness.
また、上記の含窒素化合物の中で、特にクレアチニンは、尿中の含有量がほぼ一定しているため、腎機能の有用な指標物質であり、血清クレアチニン値が測定されている。 Among the nitrogen-containing compounds described above, creatinine is a useful indicator substance for renal function because urinary content is almost constant, and serum creatinine level is measured.
腎機能が低下したときに、生体内に蓄積される上記のような含窒素化合物を除去する薬剤としては、活性炭が知られており、例えば特許文献1には、活性炭にカルボン酸またはその塩からなる化合物を被覆してなるクレアチニン吸着剤が提案されている。 Activated carbon is known as a drug that removes the above nitrogen-containing compounds accumulated in the living body when renal function is reduced. For example, Patent Document 1 discloses that activated carbon is converted from carboxylic acid or a salt thereof. A creatinine adsorbent formed by coating a compound is proposed.
また、本出願人等は、先に、陽イオン交換能が50ミリイクイバレント/100g以上の層状構造を有する粘土粒子からなる経口投与吸着剤を提案した(特許文献2参照)。
しかしながら、特許文献1などに開示されている活性炭系の吸着剤は、主として透析時に使用されるものであり、経口投与には適していない。例えば、このような吸着剤は黒い粉末であり、見映えがよくないばかりか、便秘などの障害を生じやすく、さらに、その吸着力も未だ十分でない。また、猫などのペット用に使用したときには、ペットによる食いつきが悪いという欠点がある。 However, the activated carbon-based adsorbent disclosed in Patent Document 1 is mainly used at the time of dialysis and is not suitable for oral administration. For example, such an adsorbent is a black powder, not only looks bad, but also easily causes constipation and other problems, and its adsorbing power is still not sufficient. In addition, when used for pets such as cats, there is a disadvantage that the bite by pets is poor.
また、重症の腎不全症などの患者、犬、猫等の動物においては、尿として排泄しきれない各種含窒素化合物等からなる毒素成分の一部を、腸管粘膜を通して血中の毒素成分(クレアチニン、BUN等)を吸着し、排便とともに体外に排出することが望まれているが、このような排出性の点でも、活性炭系の吸着剤は改善の余地がある。 In patients with severe renal insufficiency, animals such as dogs and cats, a part of the toxin component consisting of various nitrogen-containing compounds that cannot be excreted as urine is passed through the intestinal mucosa (creatinine). , BUN, etc.) are adsorbed and discharged out of the body together with defecation, but the activated carbon-based adsorbent also has room for improvement in terms of such discharge characteristics.
一方、特許文献2で提案されている粘土系の吸着剤は、上記のような活性炭系の吸着剤の欠点が有効に改善されているものであるが、本発明者等の研究によると、アルミニウムが体内で溶出し易いという問題があった。即ち、アルミニウムの体内での蓄積は、アルミニウム脳症(透析痴呆)やアルミニウム骨症などの健康被害をもたらすおそれのあることが知られており、このため、透析療法を受けている患者や腎臓障害のある患者に対しては、アルミニウム含有医薬の使用が制限されている。従って、ペット用においても、このようなアルミニウムが体内で溶出するような剤は、避けた方が好ましい。 On the other hand, the clay-based adsorbent proposed in Patent Document 2 is one in which the disadvantages of the above-mentioned activated carbon-based adsorbent are effectively improved. There was a problem that it was easy to elute in the body. In other words, it is known that accumulation of aluminum in the body may cause health problems such as aluminum encephalopathy (dialysis dementia) and aluminum osteopathy. For some patients, the use of aluminum-containing medication is restricted. Therefore, it is preferable to avoid such an agent that elutes aluminum in the body even for pets.
従って、本発明の目的は、クレアチニン等の含窒素化合物を、経口投与により有効に吸着除去できるとともに、アルミニウムの体内での溶出が有効に抑制された粘土系の経口投与吸着剤を提供することにある。 Accordingly, an object of the present invention is to provide a clay-based orally administered adsorbent in which nitrogen-containing compounds such as creatinine can be effectively adsorbed and removed by oral administration and the dissolution of aluminum in the body is effectively suppressed. is there.
本発明者等は、ある種の粘土系鉱物を適度に酸処理したものは、含窒素化合物を有効に吸着除去し得るとともに、アルミニウムを含有していながら、その溶出が有効に抑制されていることを見出し、本発明を完成させた。 The inventors of the present invention have been able to effectively adsorb and remove nitrogen-containing compounds obtained by appropriately acid-treating certain clay minerals, and that the elution is effectively suppressed while containing aluminum. The present invention was completed.
本発明によれば、ジオクタヘドラル型スメクタイト系粘土の酸処理により得られた活性白土からなり、レーザ回折散乱法により測定される重み付き表面積平均粒子径が10乃至700μmであり、比表面積が100乃至400m2/gの範囲にあり、且つ、安息角が40度以下であることを特徴とする経口投与吸着剤が提供される。 According to the present invention, it is composed of activated clay obtained by acid treatment of dioctahedral smectite clay, the weighted surface area average particle diameter measured by laser diffraction scattering method is 10 to 700 μm, and the specific surface area is 100 to 400 m. 2 / g Ri range near the and oral administration adsorbent angle of repose, characterized in der Rukoto 40 degrees or less is provided.
本発明によれば、また、ジオクタヘドラル型スメクタイト系粘土を、鉱酸水溶液を使用して酸処理を行い、酸処理後に水洗することにより、活性白土からなる経口投与吸着剤を製造する方法において、
前記酸処理前或いは水洗後の何れかの段階で、非破壊的な手段により、レーザ回折散乱法により測定される重み付き表面積平均粒子径を10乃至700μmの範囲に粒度調整する工程を含むことを特徴とする経口投与吸着剤の製造方法が提供される。
According to the present invention, the dioctahedral smectite clay is acid-treated using a mineral acid aqueous solution, and washed with water after the acid treatment to produce an orally administered adsorbent composed of activated clay.
Including a step of adjusting the weighted surface area average particle size measured by the laser diffraction scattering method to a range of 10 to 700 μm by a non-destructive means at any stage before the acid treatment or after washing with water. A method for producing an orally administered adsorbent is provided.
本発明の製造方法においては、
(1)前記非破壊的な手段による粒度調整を、噴霧造粒または転動造粒により行なうこと、
(2)前記酸処理を、酸濃度が20乃至45重量%となるように鉱酸を添加し、且つ80℃以上の温度に加熱することに行うこと、
が好ましい。
In the production method of the present invention,
(1) The particle size adjustment by the non-destructive means is performed by spray granulation or rolling granulation,
(2) performing the acid treatment by adding a mineral acid to an acid concentration of 20 to 45% by weight and heating to a temperature of 80 ° C. or higher;
Is preferred.
本発明の経口投与吸着剤は、後述する実施例に示されているように、含窒素化合物、特にクレアチニンや尿酸に対して、活性炭と同等あるいはそれ以上の高い吸着性を示し、腎機能低下症に対する治療薬乃至予防薬として極めて有用である。また、この吸着剤を構成する活性白土粒子は、基本的には、天然アルミノケイ酸塩であり、親水性を有し、しかも食品添加物としても認可されている。従って、家畜類は勿論のこと、ヒトにも有効に適用できる可能性がある。特に動物用ペットフード等の添加剤として有用である。 The orally administered adsorbent of the present invention, as shown in the examples described later, exhibits a high adsorbability equivalent to or higher than that of activated carbon with respect to nitrogen-containing compounds, particularly creatinine and uric acid. It is extremely useful as a therapeutic or prophylactic agent for this. Moreover, the activated clay particles constituting the adsorbent are basically natural aluminosilicates, have hydrophilicity, and are also approved as food additives. Therefore, there is a possibility that it can be effectively applied not only to livestock but also to humans. It is particularly useful as an additive for animal pet foods.
しかも重要なことは、本発明の経口投与吸着剤は、後述する実施例に示されているように、モデル胃液(pHが1.5の緩衝液)を用いて測定されたアルミニウム溶出量が1.0mg/g以下と極めて小さい。即ち、本発明では、アルミニウムを含有していながら、アルミニウムの体内での溶出が有効に抑制されており、これが、従来公知の粘土系吸着剤との大きな相違である。 Moreover, it is important that the orally administered adsorbent of the present invention has an aluminum elution amount of 1 measured using a model gastric fluid (buffer solution having a pH of 1.5) as shown in the examples described later. Very small, 0.0 mg / g or less. In other words, in the present invention, while aluminum is contained, elution of aluminum in the body is effectively suppressed, which is a great difference from conventionally known clay-based adsorbents.
また、本発明の経口投与吸着剤は、従来の粘土系の吸着剤と同様、尿酸に対しても優れた吸着性を示すことから、例えば痛風の予防や治療技術などに対して応用可能な薬剤としても使用できる。 Further, since the orally administered adsorbent of the present invention exhibits an excellent adsorptivity to uric acid as well as conventional clay-based adsorbents, it can be applied to, for example, gout prevention and treatment techniques. Can also be used.
<経口投与吸着剤>
既に述べた通り、本発明の経口投与吸着剤は、ジオクタヘドラル型スメクタイト系粘土を酸処理して得られた活性白土からなる。即ち、このような活性白土においては、スメクタイトと共存しているアルミニウム成分が有効に取り除かれており、残存するアルミニウム成分は、スメクタイト結晶構造中に安定な形で組み込まれている。このため、アルミニウム成分を含有しているにもかかわらず、生体内でのアルミニウムの溶出が有効に抑制されるという性質を有している。
<Orally administered adsorbent>
As already described, the orally administered adsorbent of the present invention comprises an activated clay obtained by acid treatment of dioctahedral smectite clay. That is, in such activated clay, the aluminum component coexisting with the smectite is effectively removed, and the remaining aluminum component is incorporated in a stable form in the smectite crystal structure. For this reason, although it contains an aluminum component, it has the property that elution of aluminum in a living body is effectively suppressed.
また、酸処理されるジオクタヘドラル型スメクタイト系粘土は、火山岩や溶岩等が海水の影響下で変成したものと考えられている。その主成分であるスメクタイトは、SiO4四面体層−AlO6八面体層−SiO4四面体層からなり、且つこれらの四面体層と八面体層が部分的に異種金属で同型置換された三層構造を基本構造(単位層)としており、このような三層構造の積層層間には、Ca,K,Na等の陽イオンや水素イオンとそれに配位している水分子が存在している。また、三層構造の八面体層中のAlの一部がMgや2価のFeに置換し、四面体層中のSiの一部がAlに置換しているため、結晶格子はマイナスの電荷を有しており、このマイナスの電荷が単位層間に存在する金属陽イオンや水素イオンにより中和されている。このようなスメクタイト系粘土には、酸性白土、ベントナイト、フラーズアースなどがあり、単位層間に存在する金属陽イオンの種類や量、及び水素イオン量などによってそれぞれ異なる特性を示す。例えば、ベントナイトでは、単位層間に存在するNaイオン量が多く、このため、水に懸濁分散させた分散液のpHが高く、一般に高アルカリ側にあり、また、水に対して高い膨潤性を示し、さらにはゲル化して固結するという性質を示す。一方、酸性白土では、単位層間に存在する水素イオン量が多く、このため、水に懸濁分散させた分散液のpHが低く、一般に酸性側にあり、また、水に対して膨潤性を示すものの、ベントナイトと比較すると、その膨潤性は総じて低く、ゲル化には至らない。 In addition, dioctahedral smectite clay treated with acid is considered to have been transformed from volcanic rocks and lava under the influence of seawater. (Iii) where the main component is smectite, which consists SiO 4 tetrahedral layers -AlO 6 octahedral layer -SiO 4 tetrahedra layer, and these tetrahedral layer and the octahedral layer are isomorphous replacement with partially different metals The layer structure is a basic structure (unit layer), and cations such as Ca, K, Na, and hydrogen ions and water molecules coordinated with them exist between the stacked layers of such a three-layer structure. . In addition, since part of Al in the octahedral layer of the three-layer structure is replaced with Mg or divalent Fe, and part of Si in the tetrahedral layer is replaced with Al, the crystal lattice has a negative charge. This negative charge is neutralized by metal cations and hydrogen ions present between the unit layers. Such smectite clays include acid clay, bentonite, fuller's earth, and the like, and exhibit different characteristics depending on the type and amount of metal cations existing between unit layers, the amount of hydrogen ions, and the like. For example, in bentonite, the amount of Na ions existing between unit layers is large, and therefore, the pH of a dispersion suspended and dispersed in water is high, generally on the high alkali side, and has high swellability with respect to water. Furthermore, it shows the property of gelling and solidifying. On the other hand, in the acid clay, the amount of hydrogen ions present between the unit layers is large, and therefore the pH of the dispersion suspended and dispersed in water is low, generally on the acidic side, and also exhibits swelling properties with respect to water. However, compared with bentonite, its swelling property is generally low, and it does not cause gelation.
このように、ジオクタヘドラル型スメクタイト系粘土は、単位層間に存在する金属陽イオンの種類などによって異なる特性を示すが、本発明において使用する活性白土では、酸処理され、単位層間に存在する金属陽イオンの大部分が水素イオンに置き換えられている。従って、活性白土の製造に使用するジオクタヘドラル型スメクタイト系粘土としては、特に制限されず、任意のものを使用することができ、例えば酸性白土であってもよいし、また、ベントナイトであってもよい。 As described above, the dioctahedral smectite clay exhibits different characteristics depending on the type of metal cation existing between the unit layers. However, the activated clay used in the present invention is acid-treated and the metal cation existing between the unit layers. Most of these are replaced by hydrogen ions. Accordingly, the dioctahedral smectite clay used for the production of the activated clay is not particularly limited, and any one can be used. For example, the clay may be acidic clay or bentonite. .
このように、本発明において経口投与吸着剤として用いる活性白土は、上記のようなスメクタイト系粘土を酸処理して得られるものであり、下記式:
Al2O3/SiO2=5.9×10−2乃至0.12
R2O/SiO2=2.0×10−3乃至2.7×10−2
MO/SiO2=2.0×10−2乃至0.11
(上記式中、Rはアルカリ金属、Mはアルカリ土類金属である)
で表されるモル組成を有している。即ち、酸処理前のスメクタイト系粘土に比して、Al2O3/SiO2モル比は比較的小さく、且つR2O/SiO2モル比及びMO/SiO2モル比はかなり小さい。これは、酸処理によって、アルミニウム成分、アルカリ金属成分及びアルカリ土類成分がかなり除去されているからである。
Thus, the activated clay used as the orally administered adsorbent in the present invention is obtained by acid treatment of the smectite clay as described above, and has the following formula:
Al 2 O 3 / SiO 2 = 5.9 × 10 −2 to 0.12
R 2 O / SiO 2 = 2.0 × 10 −3 to 2.7 × 10 −2
MO / SiO 2 = 2.0 × 10 −2 to 0.11
(In the above formula, R is an alkali metal and M is an alkaline earth metal)
It has the molar composition represented by these. That is, the Al 2 O 3 / SiO 2 molar ratio is relatively small, and the R 2 O / SiO 2 molar ratio and the MO / SiO 2 molar ratio are considerably smaller than the smectite clay before acid treatment. This is because the aluminum component, alkali metal component, and alkaline earth component are considerably removed by the acid treatment.
また、本発明において、上記のような酸処理は、胃液によって容易に溶出し得るアルミニウム成分を除去する程度に行われるものであるが、その程度は、スメクタイトに特有の層構造が維持される程度でなければならず、例えば、本発明で得られる活性白土は、スメクタイトに特有の[001]面に由来するX線回折ピークを、2θ=3乃至10度の領域に有している。標準スメクタイトの[001]面の回折ピーク面積を100%とした時の、該ピークの相対面積強度比をスメクタイト含有率とすると、本発明の経口投与吸着剤のスメクタイト含有率は1乃至12%好ましくは2乃至10%以上の範囲にある。 Further, in the present invention, the acid treatment as described above is performed to such an extent that an aluminum component that can be easily eluted by gastric juice is removed, but the degree is such that the layer structure peculiar to smectite is maintained. For example, the activated clay obtained by the present invention has an X-ray diffraction peak derived from the [001] plane peculiar to smectite in the region of 2θ = 3 to 10 degrees. When the relative area intensity ratio of the peak when the diffraction peak area of the [001] plane of standard smectite is 100% is the smectite content, the smectite content of the orally administered adsorbent of the present invention is preferably 1 to 12%. Is in the range of 2 to 10% or more.
即ち、スメクタイト系粘土は、その特有の層構造に由来して、カチオン交換容量やプロトン放出能を有しており(特許文献2参照)、このため、各種含窒素化合物等からなる毒素成分、例えば、クレアチニンや尿酸に対して優れた吸着性を示すばかりか、それ自体、親水性であるため、経口投与した場合においても便秘等の不都合を生じないという特性を示す。さらに、スメクタイト系粘土は、pHが4.8以上の領域で高い負のζ電位を示し、従って、クレアチニンや尿素等の含窒素化合物の分子を、腸内環境下(pHが中性ないし弱アルカリ領域である)で水素結合或いは双極子相互作用によって吸着するという特性をも示す。 That is, smectite clay is derived from its unique layer structure, and has a cation exchange capacity and a proton releasing ability (see Patent Document 2). Therefore, a toxin component composed of various nitrogen-containing compounds, for example, In addition to exhibiting excellent adsorptivity to creatinine and uric acid, it is hydrophilic per se, and thus exhibits no inconvenience such as constipation even when administered orally. In addition, smectite clay exhibits a high negative ζ potential in the region where the pH is 4.8 or higher, and therefore, molecules of nitrogen-containing compounds such as creatinine and urea are allowed to enter the intestinal environment (pH is neutral or weakly alkaline). It also exhibits the property of being adsorbed by hydrogen bonding or dipole interaction.
上記の説明から理解されるように、本発明で得られる活性白土は、スメクタイト系粘土に特有の構造がある程度残存しているため、クレアチニンや尿素等の含窒素化合物を吸着し得るという特性を示すものであり、例えば、前述した[001]面のX線回折ピーク面積が、前記範囲よりも小さい場合には、酸処理が必要以上に行われたこととなり、含窒素化合物に対する吸着性が不満足となってしまい(極端な場合には、シリカと同レベルになってしまう)、また、前記範囲よりも大きい場合には、酸処理が不十分であり、アルミニウム溶出量の増大を招いてしまうこととなる。 As understood from the above description, the activated clay obtained by the present invention has a characteristic that it can adsorb nitrogen-containing compounds such as creatinine and urea because the structure peculiar to smectite clay remains to some extent. For example, when the X-ray diffraction peak area of the above-mentioned [001] plane is smaller than the above range, the acid treatment is performed more than necessary, and the adsorptivity to the nitrogen-containing compound is unsatisfactory. (In an extreme case, it becomes the same level as silica), and when it is larger than the above range, the acid treatment is insufficient and the amount of aluminum elution is increased. Become.
また、本発明で経口投与吸着剤として用いる活性白土は、比較的粗大な粒径を有していることも必要であり、具体的には、レーザ回折散乱法により測定される重み付き表面積平均粒子径が10乃至700μm、好ましくは10乃至100μmである。なお、本発明の平均粒子径とは、JIS-Z-8819-2に規定されている重み付き表面積平均粒子径(ザウター径、体面積平均径)である。また、体積基準ふるい下粒度分布から、5μm以下の微粒子含有率が12体積%以下の範囲に抑制されていることが好ましい。即ち、このような比較的粗大な粒子径を有していることにより、含窒素化合物に対する吸着性を損なうことなく、アルミニウム溶出量を抑制することができる。前述した説明から理解されるように、本発明で得られる活性白土では、スメクタイトの単位層構造が残存しているため、アルミニウム成分も残存している。従って、平均粒子径が上記範囲よりも小さい場合には、経口投与したとき、これら粒子と胃液(胃酸)との接触頻度が高くなりすぎ、この結果、アルミニウム溶出量の増大を招いてしまうからである。また、平均粒子径が上記範囲よりも大きい場合には、含窒素化合物に対する吸着性が低下し、また、ペットの食いつき性も低下し、ペットに対する経口投与が困難になることもある。 The activated clay used as an orally administered adsorbent in the present invention also needs to have a relatively coarse particle size, specifically, weighted surface area average particles measured by a laser diffraction scattering method. The diameter is 10 to 700 μm, preferably 10 to 100 μm. The average particle diameter of the present invention is a weighted surface area average particle diameter (Sauter diameter, body area average diameter) defined in JIS-Z-8819-2. Moreover, it is preferable that the fine particle content of 5 μm or less is suppressed to a range of 12% by volume or less from the particle size distribution under the volume-based sieve. That is, by having such a relatively coarse particle diameter, the aluminum elution amount can be suppressed without impairing the adsorptivity to the nitrogen-containing compound. As understood from the above description, in the activated clay obtained by the present invention, since the unit layer structure of smectite remains, the aluminum component also remains. Therefore, when the average particle diameter is smaller than the above range, the frequency of contact between these particles and gastric juice (gastric acid) becomes too high when administered orally, resulting in an increase in the amount of aluminum elution. is there. In addition, when the average particle size is larger than the above range, the adsorptivity to the nitrogen-containing compound is lowered, the biting property of the pet is also lowered, and oral administration to the pet may be difficult.
さらに、本発明で得られる活性白土は、酸処理によって比表面積が増大しており、その比表面積が100乃至400m2/g、好ましくは150乃至350m2/gの範囲にある。このため、含窒素化合物に対する吸着性は損なわれず、酸処理前のスメクタイト系粘土と同等の吸着性を示す。例えば、比表面積が、上記範囲よりも大きいときには、通常、酸処理が必要以上に行われたこととなり、スメクタイト構造に由来する含窒素化合物に対する吸着性が低下してしまう。また、比表面積が上記範囲よりも小さいときには、通常、酸処理が不十分であり、このため、アルミニウム溶出量が増大してしまうという不都合を生じる。 Furthermore, the activated clay obtained by the present invention has a specific surface area increased by acid treatment, and the specific surface area is in the range of 100 to 400 m 2 / g, preferably 150 to 350 m 2 / g. For this reason, the adsorptivity with respect to a nitrogen-containing compound is not impaired, but the adsorptivity equivalent to the smectite clay before acid treatment is shown. For example, when the specific surface area is larger than the above range, the acid treatment is usually performed more than necessary, and the adsorptivity to the nitrogen-containing compound derived from the smectite structure is lowered. Further, when the specific surface area is smaller than the above range, the acid treatment is usually insufficient, which causes a disadvantage that the amount of aluminum elution increases.
上述した経口投与吸着剤として用いる活性白土は、アルミニウム溶出量を低減させるという観点から、その安息角が40度以下である。即ち、この安息角は、粒子を積み上げたときに、自由表面が限界応力状態にある場合、その面と水平面とがなす角度である(JIS-R-1600)。従って、安息角が上記範囲であることは、粒子が積み上がり難いこと、換言すると、活性白土の粒子が丸みを帯び、圧縮、衝撃、せん断、摩擦、切断などの力を活性白土に与え破壊させることによって粒度調整されたものではないことを示し、さらには、新破断面が露出していないことを示している。本発明では、このような安息角を示す活性白土を使用することにより、アルミニウム成分の表面露出が抑制され、アルミニウム溶出量を一層有効に抑制することが可能となるのである。 Activated clay used as oral adsorbents described above, from the viewpoint of reducing the aluminum dissolution amount, an angle of repose that is Ru der 40 degrees or less. In other words, this angle of repose is an angle formed by a plane and a horizontal plane when the free surface is in a critical stress state when the particles are stacked (JIS-R-1600). Therefore, if the angle of repose is in the above range, the particles are difficult to pile up. In other words, the particles of the activated clay are rounded, and the activated clay is subjected to a force such as compression, impact, shear, friction, cutting, etc. This indicates that the particle size was not adjusted, and that the new fracture surface was not exposed. In the present invention, by using the activated clay showing such an angle of repose, the surface exposure of the aluminum component is suppressed, and the aluminum elution amount can be more effectively suppressed.
このように本発明の経口投与吸着剤は、胃酸などによるアルミニウム溶出が有効に抑制されているため、経口投与によるアルミニウムの体内への蓄積を有効に回避することができ、しかも経口投与により、腎機能などの低下により体内に蓄積され、或いは腸内で産生されたり、腸肝循環により消化管内に排泄されたり、腸壁が一種の透析膜となって腸壁から分泌される尿毒症などの毒素成分及び毒素成分の前駆体、例えばクレアチニン、尿酸、インドキシル硫酸、メチルグアニジンなどを、消化管内で吸着し、便とともに体外に排出することができる。特にクレアチニンや尿酸に対して有効に作用し、これらを吸着し、体外に排出することができる。 As described above, since the orally administered adsorbent of the present invention effectively suppresses aluminum elution due to gastric acid and the like, it can effectively avoid accumulation of aluminum in the body by oral administration, and by oral administration, renal Toxins such as uremia that are accumulated in the body due to reduced function, etc., produced in the intestine, excreted in the digestive tract by enterohepatic circulation, or secreted from the intestinal wall as a kind of dialysis membrane Components and precursors of toxin components, such as creatinine, uric acid, indoxyl sulfate, methylguanidine, etc. can be adsorbed in the digestive tract and excreted out of the body together with feces. In particular, it acts effectively on creatinine and uric acid, adsorbs them and excretes them from the body.
例えば、クレアチニンは下記式(1)、また尿酸は下記式(2)に示すようにケト−エノール互変異性を示し得る含窒素環状化合物であり、後述の実施例からも分かるように、クレアチニンの吸着は、ほぼ100%である。
また、経口投与吸着剤として用いる活性白土は、天然アルミノケイ酸塩であるスメクタイト系粘土の酸処理物であり、食品添加物として認可されているばかりか、化学組成上、MgO含量が少なく、胃酸によりそれらの成分が抽出されることが少ないので、尿から析出する結晶の一つであるStruviteのMg源ともなりにくく、腸内で安定に吸着作用を示すという利点がある。 Moreover, the activated clay used as an orally administered adsorbent is an acid-treated product of smectite clay, which is a natural aluminosilicate, which is not only approved as a food additive, but also has a low MgO content due to its chemical composition, Since these components are rarely extracted, it is difficult to serve as a source of Mg for Struvite, which is one of the crystals precipitated from urine, and has an advantage of exhibiting a stable adsorption action in the intestine.
<活性白土の製造>
本発明において、上述した活性白土は、前述した種々のジオクタヘドラル型スメクタイト系粘土を、鉱酸水溶液を使用して酸処理を行い、酸処理後に水洗することにより製造されるが、特に重要な点は、酸処理前或いは酸処理された後の水洗後の何れかの段階で、非破壊的な手段により、スラリー中の粒子を、前述した重み付き表面積平均粒子径が10乃至700μm、好ましくは10乃至100μmの範囲となるように粒度調整を行うことが重要である。ここで、非破壊的な手段による粒度調整とは、摩砕などによる剪断力を伴う物理的な手段を用いず、粉体の凝集あるいは固体粒子表面の被覆によって粒径を増大させる方法で造粒する手段を意味するものであり、例えば、転動造粒、流動層造粒や噴霧造粒が、これに相当する。即ち、このような手段により粒度調整を行うことにより、特に新破断面を発生させることなく、前述した粒度を有する活性白土粒子を得ることができ、このような粒子は、例えば安息角が前述した範囲となり、アルミニウム溶出量を著しく低減させることができる。また、このような方法で、上記のような平均粒径に調整されたものは、一般に、体積基準ふるい下粒度分布から、5μm以下の微粒子含有率も前述した12体積%以下の範囲となる。一例として、実施例1で得られた試料の重み付き表面積平均粒子径は14μmであり、微粒子含有率は6%の粒子であった。
以下、このような 粒度調整手段を考慮しながら、その製造工程を説明する。
<Manufacture of activated clay>
In the present invention, the activated clay described above is produced by subjecting the above-mentioned various dioctahedral smectite clays to acid treatment using a mineral acid aqueous solution and washing with water after the acid treatment. In any stage before the acid treatment or after the water treatment after the acid treatment, the particles in the slurry have a weighted surface area average particle diameter of 10 to 700 μm, preferably 10 to It is important to adjust the particle size so as to be in the range of 100 μm. Here, particle size adjustment by non-destructive means means granulation by a method of increasing the particle size by agglomeration of powder or coating of the surface of solid particles without using physical means accompanied by shearing force such as grinding. For example, rolling granulation, fluidized bed granulation, and spray granulation correspond to this. That is, by adjusting the particle size by such means, it is possible to obtain activated clay particles having the above-mentioned particle size without generating a new fracture surface, and such particles have, for example, the angle of repose described above. Thus, the amount of aluminum elution can be significantly reduced. In addition, those adjusted to the average particle size as described above by such a method generally have a fine particle content of 5 μm or less within the above-mentioned range of 12% by volume or less from the particle size distribution under the volume-based sieve. As an example, the sample obtained in Example 1 had a weighted surface area average particle size of 14 μm and a fine particle content of 6%.
Hereinafter, the manufacturing process will be described in consideration of such particle size adjusting means.
先ず、原料として用いるスメクタイト系粘土は、必要により石砂分離、浮力選鉱、磁力選鉱、水簸、風簸等の精製操作に賦した後、酸処理を行うが、酸処理に先立って、上記で述べたように、転動造粒や噴霧造粒などの非破壊的手段によって粒度調整を行うことができる。また、このような粒度調整を、酸処理がなされた後の水洗後に行う場合には、通常の破壊的手段、例えばボールミルなどの粉砕機を用いた粉砕などによって、適度な粗粒(例えば、重み付き表面積平均粒子径が10乃至700μm程度の範囲)に予備的に粒度調整しておくとことが好適である。即ち、この際の粘土粒径が必要以上に大きいと、酸処理を均一に行うことが困難となるおそれがあるからである。 First, the smectite clay used as a raw material is subjected to refining operations such as stone sand separation, buoyancy beneficiation, magnetic beneficiation, water tank, wind drought, etc., if necessary, and then acid treatment, but prior to acid treatment, As stated, the particle size can be adjusted by non-destructive means such as rolling granulation or spray granulation. In addition, when such particle size adjustment is performed after washing with water after acid treatment, moderate coarse particles (for example, weights) are obtained by ordinary destructive means, for example, pulverization using a pulverizer such as a ball mill. It is preferable that the particle size is preliminarily adjusted to a surface area average particle diameter of about 10 to 700 μm. That is, if the clay particle size at this time is larger than necessary, it may be difficult to perform the acid treatment uniformly.
転動造粒により、前述した範囲に粒度調整する場合には、粘土の塊状物を造粒機内に投入し、塊状物を転がしながら水を噴霧していけばよい。一方、噴霧造粒する場合には、原料粘土を水に分散させたスラリーを調製し(通常、1乃至15重量%程度)、このスラリーを噴霧することにより、前述した範囲に粒度調整することができる。この場合、スラリー濃度や噴霧圧力などによって粒子径を調整することができるが、原料粘土としてベントナイトを用いた場合には、スラリー濃度をあまり高くすると粒子の膨潤及びゲル化を生じてしまうが、噴霧造粒する場合のスラリー濃度はかなり低濃度であるため、このような不都合は回避することができる。 When the particle size is adjusted to the above-described range by rolling granulation, a clay lump may be put into the granulator and sprayed with water while rolling the lump. On the other hand, in the case of spray granulation, a slurry in which raw clay is dispersed in water is prepared (usually about 1 to 15% by weight), and this slurry is sprayed to adjust the particle size to the above-mentioned range. it can. In this case, the particle diameter can be adjusted by the slurry concentration, spraying pressure, etc., but when bentonite is used as the raw clay, if the slurry concentration is too high, particle swelling and gelation will occur. Such inconvenience can be avoided because the slurry concentration when granulating is considerably low.
酸処理は、硫酸、塩酸、硝酸等の鉱酸を用いて行われるが、取り扱い性、酸処理速度などの観点から、硫酸が最も好適に使用される。また、このような鉱酸は、酸濃度が20乃至45重量%となるように、上記の粘土粒子(或いは粘土粒子の水性スラリー)と混合し、且つ80℃以上、特に85乃至95℃の範囲に加熱することにより酸処理を行うことが好適である。即ち、このような条件で酸処理を行うことにより、適度な時間(1乃至20時間程度)での処理により、前述したようにスメクタイト系粘土に特有の構造を維持しつつ、アルミニウム成分等を除去することができるからである。例えば、上記の条件を外れるような範囲で酸処理を行うと、適度な酸処理に必要以上の時間を要したり、或いは酸処理が迅速に進行したりしてしまい、そのコントロールが困難となるおそれがあるからである。 The acid treatment is performed using a mineral acid such as sulfuric acid, hydrochloric acid, nitric acid, etc., but sulfuric acid is most preferably used from the viewpoints of handleability and acid treatment speed. Further, such a mineral acid is mixed with the above clay particles (or an aqueous slurry of clay particles) so as to have an acid concentration of 20 to 45% by weight, and in the range of 80 ° C. or higher, particularly 85 to 95 ° C. It is preferable to carry out the acid treatment by heating. That is, by performing the acid treatment under such conditions, the aluminum component and the like are removed while maintaining the structure peculiar to the smectite clay as described above by the treatment in an appropriate time (about 1 to 20 hours). Because it can be done. For example, if the acid treatment is performed in a range that does not satisfy the above conditions, it takes more time than necessary for an appropriate acid treatment, or the acid treatment proceeds rapidly, and the control becomes difficult. Because there is a fear.
上記のような酸処理後は、水洗して酸や酸処理によって生成した不要な塩を除去する。 After the acid treatment as described above, washing with water is performed to remove the acid and unnecessary salts generated by the acid treatment.
この場合、酸処理前に粒度調整を行っておけば、酸処理工程では、その粒度は、実質上、そのまま維持されるため、直ちに乾燥を行って製品とすることができる。かかる乾燥は、熱風乾燥等の任意の手段により行うことができる。 In this case, if the particle size is adjusted before the acid treatment, the particle size is substantially maintained as it is in the acid treatment step, so that it can be immediately dried to obtain a product. Such drying can be performed by any means such as hot air drying.
一方、酸処理前に、予備的な粒度調整のみしか行われていない場合には、水洗後に非破壊的な手段によって前述した範囲に粒度調整が行われる。この場合の非破壊的な粒度調整は、転動造粒や噴霧造粒によって行われる。 On the other hand, when only preliminary particle size adjustment is performed before the acid treatment, the particle size adjustment is performed in the above-described range by non-destructive means after washing with water. In this case, nondestructive particle size adjustment is performed by rolling granulation or spray granulation.
このようにして得られる活性白土粒子は、前述した組成、粒度分布及び比表面積を有しており、クレアチニンや尿酸等の含窒素化合物に対する吸着性に優れ、さらにはアルミニウム溶出量も低減されており、経口投与吸着剤として、含窒素化合物などからなる毒素成分を除去するためにヒトやペットなどに使用される。 The activated clay particles thus obtained have the composition, particle size distribution and specific surface area described above, have excellent adsorptivity to nitrogen-containing compounds such as creatinine and uric acid, and also have a reduced aluminum elution amount. As an orally administered adsorbent, it is used in humans and pets to remove toxin components consisting of nitrogen-containing compounds.
尚、本発明の経口投与吸着剤は、必要により、食品添加物として認可されている可食性有機酸やその塩などと混合して使用することにより、尿結石症の治療・予防剤としての効果を持たせることも可能であり、また、制酸性を高めるために、炭酸カルシウムと併用することもできる。しかしながら、他の成分との混合は、新破断面を生成しない方法に限定される。従って、本発明の経口投与吸着剤は、他の成分とは混合せず、単独で使用することが最も好適である。 In addition, the orally administered adsorbent of the present invention can be used as a therapeutic / preventive agent for urinary stone disease by using it in admixture with edible organic acids or salts thereof approved as food additives, if necessary. It can also be provided, and can also be used in combination with calcium carbonate to increase antacidity. However, mixing with other components is limited to methods that do not generate new fracture surfaces. Therefore, the orally administered adsorbent of the present invention is most preferably used alone without being mixed with other components.
(1)粒度分布測定
レーザ回折式粒度分布測定装置Mastersizer Hydro 2000Gで水を分散媒とし、ポンプ速度2000rpm、攪拌速度500rpm、チップ移動50%の条件で、試料を添加し事前分散無しで粒度分布を測定した。得られた体積基準ふるい下粒度分布から、5μm以下の微粒子含有率(体積%)とJIS-Z-8819-2に規定されている重み付き表面積平均粒子径(D[3,2])を算出した。
(1) Particle size distribution measurement With the Mastersizer Hydro 2000G laser diffraction particle size distribution analyzer, water is used as the dispersion medium, the sample is added and the particle size distribution is obtained without prior dispersion under the conditions of a pump speed of 2000 rpm, a stirring speed of 500 rpm, and a tip movement of 50%. It was measured. Calculate the particle size distribution (volume%) of 5μm or less and the weighted surface area average particle size (D [3,2]) specified in JIS-Z-8819-2 from the obtained particle size distribution under the volume-based sieve. did.
(2)比表面積
カルロエルバ社製Sorptomatic Series 1900を使用し、窒素吸着等温線を測定した。比圧0.2以下の吸着枝側窒素吸着等温線からBET法で比表面積を求めた。
(2) Specific surface area A Sorptomatic Series 1900 manufactured by Carlo Elba was used to measure the nitrogen adsorption isotherm. The specific surface area was determined by the BET method from the adsorption side nitrogen adsorption isotherm with a specific pressure of 0.2 or less.
(3)安息角
ホソカワミクロン(株)製パウダテスタ PT-Rを用いて安息角を測定した。
(3) Angle of repose The angle of repose was measured using a powder tester PT-R manufactured by Hosokawa Micron Corporation.
(4)スメクタイト含有率
試料1gに10vol%エチレングリコール/エタノール溶液を加え、50℃で一晩乾燥させる。得られた試料を、日本フィリップス(株)製のX線回折装置PW1830を用いて測定した。
ターゲット Cu
フィルター Ni
検出器 プロポーショナルカウンター
電圧 40KVP
電流 50mA
走査速度 1°/min
スリット DS:1/4° RS:0.1mm SS:1/4°
照射角 6°
走査範囲 3〜10°
スメクタイト含有率は、日本粘土学会標準粘土試料JCSS-3101のX線回折図のピーク面積を100%とし、各試料のそれの相対面積強度比(%)で示した。
(4) Smectite content rate A 10 vol% ethylene glycol / ethanol solution is added to 1 g of a sample and dried at 50 ° C. overnight. The obtained sample was measured using an X-ray diffractometer PW1830 manufactured by Nippon Philips Co., Ltd.
Target Cu
Filter Ni
Detector proportional counter voltage 40KVP
Current 50mA
Scanning speed 1 ° / min
Slit DS: 1/4 ° RS: 0.1 mm SS: 1/4 °
Irradiation angle 6 °
Scanning range 3-10 °
The smectite content was expressed as the relative area intensity ratio (%) of each sample, with the peak area of the X-ray diffraction pattern of the Japan Clay Society standard clay sample JCSS-3101 as 100%.
(5)クレアチニン吸着試験
試料各400mgに濃度0.1g/Lの標準液0.5mLを加え、pH6.86緩衝液3.0mLを加え振り混ぜた。室温で10分間放置してから2500rpmで15分間、遠心分離した。
上清を2.0mL採取し、30℃の水槽につけた。ピクリン酸試液(8.7mmol/L)、0.75N水酸化ナトリウム溶液を1.0mLずつ加え、攪拌した。30℃の水槽に20分間放置した後、505nmの吸光度を測定した。
(5) Creatinine adsorption test To each 400 mg of the sample, 0.5 mL of a standard solution having a concentration of 0.1 g / L was added, and 3.0 mL of pH 6.86 buffer was added and shaken. The mixture was allowed to stand at room temperature for 10 minutes and then centrifuged at 2500 rpm for 15 minutes.
2.0 mL of the supernatant was collected and placed in a 30 ° C. water bath. Picric acid test solution (8.7 mmol / L) and 0.75N sodium hydroxide solution were added in an amount of 1.0 mL each and stirred. After being left in a 30 ° C. water bath for 20 minutes, the absorbance at 505 nm was measured.
(6)Al溶出試験
1N-HClを41.4mL採取し、KClを3.73g添加し、1000mLにメスアップして調製したモデル胃液25mLに試料0.5gを添加した。恒温槽中に設置したEyela Shaker "MINI"SS-80を用い、目盛5で37℃5時間振盪した。2500rpmで15分間、遠心分離して得られた上澄み液中のAl濃度を原子吸光光度計で測定した。
(6) Al dissolution test
41.4 mL of 1N-HCl was collected, 3.73 g of KCl was added, and 0.5 g of a sample was added to 25 mL of model gastric fluid prepared by measuring up to 1000 mL. Using an Eyela Shaker “MINI” SS-80 installed in a thermostatic chamber, it was shaken at 37 ° C. for 5 hours on a scale 5. The Al concentration in the supernatant obtained by centrifugation at 2500 rpm for 15 minutes was measured with an atomic absorption photometer.
(実施例1)
新潟県胎内市羽黒山産酸性白土を肉引き器で粗砕してから転動造粒機を用いて造粒した(造粒物Aとする)。この造粒物A40.7gに75%硫酸45.6gと72mlの水を加え、スラリーを調製した。時々かき混ぜながら90℃で6時間加熱した。その後、塩基性成分が沈殿しないようにろ過、水洗し110℃で一晩乾燥し試料を得た。このものは、流動性の良い細粒であった。物性測定を行い、結果を表1に示す。
Example 1
The acid clay from Haguroyama, Niigata Prefecture, was crushed with a meat puller and granulated using a rolling granulator (referred to as granulated product A). To 40.7 g of this granulated product A, 45.6 g of 75% sulfuric acid and 72 ml of water were added to prepare a slurry. Heated at 90 ° C. for 6 hours with occasional mixing. Then, it filtered, washed with water so that a basic component might not precipitate, and dried at 110 degreeC overnight, and the sample was obtained. This was a fine particle with good fluidity. The physical properties were measured and the results are shown in Table 1.
(実施例2)
実施例1で得た造粒物A33.4gに75%硫酸27.7gと67mlの水を加え、スラリーを調製した。その後は実施例1と同様にして行い、試料を得た。物性測定を行い、結果を表1に示す。
(Example 2)
A slurry was prepared by adding 27.7 g of 75% sulfuric acid and 67 ml of water to 33.4 g of the granulated product A obtained in Example 1. Thereafter, the same procedure as in Example 1 was performed to obtain a sample. The physical properties were measured and the results are shown in Table 1.
(実施例3)
新潟県新発田市小戸産酸性白土Aを肉引き器で粗砕した。この酸性白土1kgを水11Lに分散し遠心分離して固形分4.9%の懸濁液を得た。この懸濁液を噴霧乾燥して顆粒440gを得た。次に、2Lの撹拌翼の付いたガラス製フラスコに、水750mL、続いて濃硫酸(96%)500gをゆっくりと添加し、さらに先ほど得た顆粒を200g分散させ、90℃まで2時間かけて昇温し、8時間その温度を維持した後、1時間で50℃まで冷却した。このスラリーを減圧ろ過し、ケーキを回収した。このケーキに蒸留水を4リットル加え再スラリー化後、ろ過した。この洗浄操作を3回繰り返した。回収したケーキを110℃で一晩乾燥した。乾燥後の重量は134gであった。物性測定を行い、結果を表1に示す。
(Example 3)
The acid white clay A from Odo, Shibata City, Niigata Prefecture was crushed with a meat puller. 1 kg of this acid clay was dispersed in 11 L of water and centrifuged to obtain a suspension having a solid content of 4.9%. This suspension was spray-dried to obtain 440 g of granules. Next, 750 mL of water and then 500 g of concentrated sulfuric acid (96%) are slowly added to a glass flask equipped with a 2 L stirring blade, and 200 g of the granules obtained above are further dispersed, and the mixture is heated to 90 ° C. over 2 hours. The temperature was raised and the temperature was maintained for 8 hours, and then cooled to 50 ° C. in 1 hour. This slurry was filtered under reduced pressure to recover the cake. Four liters of distilled water was added to this cake, and after reslurry, it was filtered. This washing operation was repeated three times. The collected cake was dried at 110 ° C. overnight. The weight after drying was 134 g. The physical properties were measured and the results are shown in Table 1.
(実施例4)
新潟県胎内市産酸性白土を原料として用い、この原料を粗砕、混練し5mm径に造粒した。次に、ビーカーに34重量%の硫酸水溶液0.2リットルに、造粒した固形分62%の原料粘土を150g添加し、酸処理を95℃で14時間行い、濾過、水洗後の水洗上がり品を得た。それを28メッシュ篩に通し、水分28%に調整後、転動造粒機で成粒し、試料を得た。物性測定を行い、結果を表1に示す。
Example 4
Using the acid clay from Niigata Prefecture's womb city as a raw material, this raw material was roughly crushed, kneaded and granulated to a diameter of 5 mm. Next, 150 g of granulated raw material clay with a solid content of 62% is added to 0.2 liter of 34 wt% sulfuric acid aqueous solution in a beaker, acid treatment is performed at 95 ° C. for 14 hours, and the product after washing with water after filtration and washing with water Got. It was passed through a 28 mesh sieve, adjusted to a moisture of 28%, and granulated with a rolling granulator to obtain a sample. The physical properties were measured and the results are shown in Table 1.
(比較例1)
水澤化学工業(株)製活性白土であるガレオンアースV2を用いた。物性測定を行い、結果を表1に示す。
(Comparative Example 1)
Galeon Earth V2 which is activated clay made by Mizusawa Chemical Co., Ltd. was used. The physical properties were measured and the results are shown in Table 1.
(比較例2)
実施例4において、硫酸水溶液の濃度を52重量%にし、酸処理を95℃で24時間に変更した以外は、同様にして行い得られた水洗上がり品を乾燥、粉砕し、試料を得た。物性測定を行い、結果を表1に示す。
(Comparative Example 2)
In Example 4, except that the concentration of the sulfuric acid aqueous solution was changed to 52% by weight and the acid treatment was changed to 95 ° C. for 24 hours, the water-washed product obtained in the same manner was dried and pulverized to obtain a sample. The physical properties were measured and the results are shown in Table 1.
(比較例3)
新潟県胎内市産酸性白土を原料として用い、この原料を粗砕、混練し5mm径に造粒した。次に、ビーカーに12.5重量%の硫酸水溶液0.15リットルに、造粒した固形分62%の原料粘土を225g添加し、酸処理を90℃で15時間行い、濾過、水洗後の水洗上がり品を得た。次に、この水洗上がり品を水に分散し固形分10%に調整してから、チューブミルで粉砕し、篩い分けした後ろ過し得られたケーキをスピンフラッシュドライヤーで乾燥し試料を得た。物性測定を行い、結果を表1に示す。
(Comparative Example 3)
Using the acid clay from Niigata Prefecture's womb city as a raw material, this raw material was roughly crushed, kneaded and granulated to a diameter of 5 mm. Next, 225 g of granulated raw material clay with a solid content of 62% is added to 0.15 liter of 12.5 wt% sulfuric acid aqueous solution in a beaker, acid treatment is performed at 90 ° C. for 15 hours, filtration, and washing with water after washing with water. I got a finished product. Next, this water-washed product was dispersed in water and adjusted to a solid content of 10%, then pulverized with a tube mill, sieved, and then filtered to obtain a sample by drying with a spin flash dryer. The physical properties were measured and the results are shown in Table 1.
(比較例4)
新潟県新発田市小戸産酸性白土Bを孔径0.8mmのダイスを有する押出成形機で成形し試料得た。物性測定を行い、結果を表1に示す。
(Comparative Example 4)
Samples were obtained by molding acid clay B from Odo, Shibata City, Niigata Prefecture, with an extruder having a die with a hole diameter of 0.8 mm. The physical properties were measured and the results are shown in Table 1.
(比較例5)
新潟県新発田市小戸産酸性白土Bを乳鉢で粉砕し試料を得た。物性測定を行い、結果を表1に示す。
(Comparative Example 5)
A sample was obtained by pulverizing acid clay B from Odo, Shibata City, Niigata Prefecture, with a mortar. The physical properties were measured and the results are shown in Table 1.
(比較例6)
日本薬局方に準拠した合成珪酸アルミニウムを用いた。物性測定を行い、結果を表1に示す。
(Comparative Example 6)
Synthetic aluminum silicate conforming to the Japanese Pharmacopoeia was used. The physical properties were measured and the results are shown in Table 1.
Claims (4)
前記酸処理前或いは水洗後の何れかの段階で、非破壊的な手段により、レーザ回折散乱法により測定される重み付き表面積平均粒子径を10乃至700μmの範囲に粒度調整する工程を含むことを特徴とする経口投与吸着剤の製造方法。 In the method for producing an orally administered adsorbent consisting of activated clay by acid treatment of a dioctahedral smectite clay using an aqueous mineral acid solution and washing with water after the acid treatment,
Including a step of adjusting the weighted surface area average particle size measured by the laser diffraction scattering method to a range of 10 to 700 μm by a non-destructive means at any stage before the acid treatment or after washing with water. A method for producing an orally administered adsorbent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007153182A JP5146643B2 (en) | 2007-06-08 | 2007-06-08 | Orally administered adsorbent with excellent adsorption characteristics of nitrogen-containing compounds and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007153182A JP5146643B2 (en) | 2007-06-08 | 2007-06-08 | Orally administered adsorbent with excellent adsorption characteristics of nitrogen-containing compounds and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008303189A JP2008303189A (en) | 2008-12-18 |
JP5146643B2 true JP5146643B2 (en) | 2013-02-20 |
Family
ID=40232213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007153182A Expired - Fee Related JP5146643B2 (en) | 2007-06-08 | 2007-06-08 | Orally administered adsorbent with excellent adsorption characteristics of nitrogen-containing compounds and method for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5146643B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5841414B2 (en) * | 2011-11-29 | 2016-01-13 | クニミネ工業株式会社 | Clay powder in which hydrogen ions are present between layers and method for producing the same |
DE102012209411A1 (en) | 2012-06-04 | 2013-12-05 | Fim Biotech Gmbh | Mineral compound for the reduction of inorganic phosphates, in particular in the context of renal replacement therapy |
JP6618769B2 (en) * | 2015-01-09 | 2019-12-11 | 水澤化学工業株式会社 | Activated clay particles |
JP6910136B2 (en) * | 2016-01-28 | 2021-07-28 | 水澤化学工業株式会社 | Adsorbent for purines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639492A (en) * | 1995-01-13 | 1997-06-17 | Amcol International Corporation | Method and composition for achieving animal weight gain with mycotoxin-contaminated animal food |
JP4945101B2 (en) * | 2004-08-27 | 2012-06-06 | 黒崎白土工業株式会社 | Orally administered adsorbent for creatinine and uric acid adsorption |
-
2007
- 2007-06-08 JP JP2007153182A patent/JP5146643B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2008303189A (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2620506B2 (en) | Method for producing a sorbent for absorbing liquid | |
WO2011091262A2 (en) | Hybrid animal litter composition | |
JP5146643B2 (en) | Orally administered adsorbent with excellent adsorption characteristics of nitrogen-containing compounds and method for producing the same | |
JPH05503432A (en) | Animal feed additives and methods for inactivating mycotoxins present in animal feed | |
CA2948606A1 (en) | Method for the production of granules comprising surface-reacted calcium carbonate | |
Rathnayake et al. | Essence of hydroxyapatite in defluoridation of drinking water: A review | |
JP6858055B2 (en) | Lead adsorbent | |
DE102006041553B4 (en) | Mineral granules, process for its preparation and use of the granules | |
JPWO2014003120A1 (en) | Granulated product and production method thereof | |
CN1861095A (en) | Load type super-fine copper-powder copper-complementary agent, its prepn. method and use | |
JP4175726B2 (en) | Pet toilet sand | |
JP2532515B2 (en) | Blood coagulant | |
DE102004050058A1 (en) | Process for the preparation of a particular liquid animal waste absorbing bedding agent for pets | |
WO2003077674A1 (en) | A feed additive of nanometer size, a process preparing the same and a feed containing the feed additive of nanometer size | |
CN106431453A (en) | Preparing method of hydrous aluminosilicate clay cat litter | |
JPH0665892A (en) | Pitch adsorbent | |
US9585913B2 (en) | Clay mineral for reducing inorganic phosphates, in particular in renal replacement therapy | |
Berillo et al. | The review of oral adsorbents and their properties | |
KR20110122894A (en) | Manufacturing method of deodorant / dehumidifier with deodorization and dehumidification function | |
Singh et al. | Design and development of montmorillonite-sodium alginate microbeads for oral sustained delivery of cefaclor | |
JP4748882B2 (en) | Excrement treatment agent | |
JP7145020B2 (en) | purification material | |
JP4945101B2 (en) | Orally administered adsorbent for creatinine and uric acid adsorption | |
WO2011131629A1 (en) | Adsorbent for adsorption of basic compounds | |
JP2005288423A (en) | Adsorption base material for acetaldehyde, or the like, and chemical preparation base material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121030 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20121113 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121113 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5146643 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151207 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |